Composition for reducing uric acid as well as preparation and application thereof

Abstract

The invention belongs to the technical field of food health care, and particularly relates to a uric acid reducing composition as well as preparation and application thereof. The uric acid reducing composition comprises 40-80 parts of collagen peptide, 10-20 parts of sophora flower bud extract, 8-15 parts of lily powder, 5-15 parts of chitosan oligosaccharide, 5-15 parts of papaya powder, 5-15 parts of gardenia extract and 1-4 parts of multivitamins. The uric acid reducing composition is obtained on the basis of medicinal and edible raw materials, is convenient to carry and eat, has natural and healthy components, does not have toxic or side effect, has good health care and prevention effects on people with high uric acid and high risk of high uric acid, and is suitable for long-term taking to achieve the effect of reducing uric acid.

Description

Technical Field

[0001] The present invention belongs to the technical field of food health care, and particularly relates to a uric acid-lowering composition and its preparation and application. Background Art

[0002] Hyperuricemia is a metabolic disease that can cause gout, chronic kidney disease, and insulin resistance. Hyperuricemia can accelerate the occurrence and development of vascular lesions and impaired glucose tolerance, and is closely related to diseases such as hypertension, atherosclerosis, coronary heart disease, lipid metabolism disorders, obesity, and sexual dysfunction. The pathogenesis of hyperuricemia includes excessive production and / or reduced excretion of uric acid.

[0003] The sources of uric acid in the human body are divided into endogenous and exogenous. Exogenous uric acid comes from food and accounts for 20% of the body's uric acid sources; endogenous uric acid comes from the synthesis of amino acids, phosphoribose, and other small molecules in the body and the catabolism of nucleic acids, accounting for 80% of the body's uric acid sources. Uric acid is the end product of human purine metabolism and is generated from hypoxanthine and xanthine under the action of xanthine oxidase (XOD). Almost all gout patients are caused by the inability of uric acid in the kidneys to be smoothly excreted from the body, resulting in an increase in blood uric acid levels. At the same time, due to the lack of uricase in the human body, it cannot be further decomposed into soluble allantoin, making humans extremely prone to hyperuricemia.

[0004] Currently, there are mainly two types of drugs for the treatment of hyperuricemia: (1) Drugs that reduce uric acid production: Allopurinol or febuxostat, which are very easily absorbed after oral administration. As inhibitors of xanthine oxidase, they can reduce the amount of uric acid produced in the body; (2) Drugs that promote uric acid excretion: Probenecid, sulfinpyrazone, and benzbromarone can help the human body excrete excessive uric acid in the kidneys. However, these drugs have large toxic and side effects, and patients often cannot tolerate them, which limits their use.

[0005] Therefore, exploring safe and non-toxic uric acid-lowering products has become a trend. To reduce the huge losses caused by this disease to society, solve the problems of the majority of patients, and improve the quality of life of patients, it is urgent to develop a drug composition with good uric acid-lowering efficacy, quick results, small toxic and side effects, and low cost. Summary of the Invention

[0006] The purpose of the present invention is to provide a uric acid-lowering composition.

[0007] Another purpose of the present invention is to provide a preparation method of the above composition.

[0008] Another purpose of the present invention is to provide the application of the above uric acid-lowering composition.

[0009] According to a uric acid-lowering composition of a specific embodiment of the present invention, by weight, the raw materials of the composition include: 40 - 80 parts of collagen peptide, 10 - 20 parts of sophora japonica extract, 8 - 15 parts of lily powder, 5 - 15 parts of chitosan oligosaccharide, 5 - 15 parts of papaya powder, 5 - 15 parts of gardenia extract, 1 - 4 parts of compound vitamins.

[0010] A uric acid - lowering composition according to a specific embodiment of the present invention, wherein the compound vitamins include vitamin B6 and vitamin C.

[0011] A uric acid - lowering composition according to a specific embodiment of the present invention, the compound vitamins further include vitamin B12 and vitamin D. The above - mentioned compound vitamins include, but are not limited to, one or more of vitamin B6, vitamin B12, and vitamin D3.

[0012] A uric acid - lowering composition according to a specific embodiment of the present invention, wherein the collagen peptide is pure fish - scale collagen peptide.

[0013] A uric acid - lowering composition according to a specific embodiment of the present invention, wherein the molecular weight of the chitosan oligosaccharide is not greater than 2000 Da.

[0014] Meanwhile, the quercetin content of the sophora japonica extract is not less than 90%.

[0015] A preparation method of a uric acid - lowering composition according to a specific embodiment of the present invention. By weight, take 40 - 80 parts of collagen peptide, 10 - 20 parts of sophora japonica extract, 8 - 15 parts of lily powder, 5 - 15 parts of chitosan oligosaccharide, 5 - 15 parts of papaya powder, 5 - 15 parts of gardenia extract, and 1 - 4 parts of compound vitamins, and mix them evenly to obtain.

[0016] The present invention also provides the application of the above - mentioned uric acid - lowering composition in the preparation of foods, health - care / functional foods.

[0017] A health - care product according to a specific embodiment of the present invention, the health - care product contains the above - mentioned uric acid - lowering composition.

[0018] A health - care product according to a specific embodiment of the present invention, the health - care product is oral liquid, liquid beverage, solid beverage, jelly or candy.

[0019] The health - care product includes additives, and the additives are selected from at least one of fillers, diluents, lubricants, glidants, surfactants, solvents, flavoring agents, stabilizers, colorants, and preservatives.

[0020] The fillers or diluents described above include saccharides such as lactose, sucrose, glucose, mannitol, sorbitol, and dextrin; starches such as starch, pregelatinized starch, and dextrin; celluloses such as microcrystalline cellulose, gum arabic, fenugreek gum, and dextran; inorganic salts such as calcium sulfate, calcium hydrogen phosphate, pharmaceutical calcium carbonate, light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate, and magnesium aluminum silicate.

[0021] The lubricants or glidants or anti-adhesives described above include stearic acid; metal salts of stearic acid such as calcium stearate or magnesium stearate; talc powder; colloidal silica; microsilica, hydrogenated vegetable oil; polyethylene glycol, lauryl sulfates such as sodium lauryl sulfate or magnesium lauryl sulfate; silicates such as silica anhydride or hydrated silicate salts, etc.

[0022] The disintegrants described above include cellulose derivatives such as low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, or cross-linked sodium carboxymethyl cellulose; cross-linked polyvinylpyrrolidone; and chemically modified starches / celluloses, such as carboxymethyl starch or sodium carboxymethyl starch.

[0023] The surfactants described above include Tween-80, sodium dodecyl sulfate, sodium stearate sulfonate, etc.

[0024] The antioxidants described above include sodium bisulfite, sodium metabisulfite, sodium sulfite, anhydrous sodium sulfite, sodium thiosulfate, methionine, thiourea, phosphoric acid, citric acid, etc.

[0025] The preservatives or antibacterial agents described above include benzoic acid and sodium benzoate, sorbic acid, ethanol, parabens (parabens), benzalkonium bromide, o-phenylphenol, benzyl alcohol, phenethyl alcohol, sodium propionate, sorbic acid, eucalyptus oil, cinnamon oil, and peppermint oil, etc.

[0026] The flavoring agents described above include sweeteners such as sodium saccharin, aspartame, syrup, stevioside, mannitol, sorbitol, mannose, galactose, maltose, fructose, glucose, sucrose, etc.; sour flavoring agents such as citric acid, malic acid, or tartaric acid; and flavoring agents such as fennel oil, peppermint oil, menthol, peppermint water, cinnamon oil, lemon essence, lemon oil, and various flavored spices, etc.

[0027] Advantages of the present invention: 1) The present invention obtains a uric acid-lowering composition based on raw materials of both medicine and food, which is convenient to carry and consume, and has natural, healthy, non-toxic side effects. It has good health care and preventive effects on people with high uric acid and those at high risk of high uric acid, and is suitable for long-term use to achieve the effect of lowering uric acid.

[0028] 2) The combination of the components in the present invention has a synergistic effect on the uric acid lowering effect. Quercetin in the sophora flower extract, colchicine in the lily powder, flavonoid compounds in the papaya powder, geniposide in the gardenia extract, etc. all have the activity of inhibiting xanthine oxidase; vitamin C can increase the clearance rate of uric acid by the kidneys and promote uric acid excretion; vitamin B6, vitamin B12, and vitamin D3 can reduce uric acid levels and serum creatinine levels, and can reduce kidney damage caused by uric acid; chitosan oligosaccharide can promote the excretion of intracellular uric acid and inhibit uric acid absorption; as the component with the highest content, collagen peptide can produce a synergistic effect with other components, enhance the inhibitory effect on xanthine oxidase activity, effectively reduce the uric acid production amount of cells, improve the activities of superoxide dismutase (SOD) and catalase (CAT) in the liver and kidney tissues, have a certain degree of protective effect on the liver and kidney, and at the same time can reduce the reabsorption of uric acid by regulating the expression level of kidney-related urate transporter proteins and promote the excretion of uric acid. Detailed implementation mode

[0029] To make the objectives, technical solutions and advantages of the present invention clearer, the technical solutions of the present invention will be described in detail below. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other implementation manners obtained by those of ordinary skill in the art without creative efforts shall fall within the scope protected by the present invention.

[0030] The present invention provides a uric acid composition, comprising the following raw materials in parts by weight: 60 parts of collagen peptide, 16 parts of sophora flower extract, 12 parts of lily powder, 10 parts of chitosan oligosaccharide, 10 parts of papaya powder, 10 parts of gardenia extract, 2 parts of compound vitamin, wherein the compound vitamin is vitamin B6: vitamin B12: vitamin D3: vitamin C = 1: 1: 1: 3, wherein, the collagen peptide is pure fish scale collagen peptide, the quercetin content of the above sophora flower extract is not less than 90%, and the molecular weight of the above chitosan oligosaccharide is not more than 2000 Da.

[0031] The above raw materials can all be obtained through commercial channels.

[0032] Sophora flower extract, alias: isoquercitrin; isoquercetin; apocynin. The plant source is the flower buds of the leguminous plant Sophora japonica. Pharmacological effects: treating chronic bronchitis, having anti-inflammatory effects, vitamin P-like effects, having the effects of maintaining vascular resistance, reducing its permeability, reducing brittleness, etc., having a lipid-removing effect on the liver with fatty infiltration, antiviral effects and inhibiting aldose reductase effects.

[0033] Lily powder is made from lilies. Lily powder is the starch of the dried fleshy scales of lilies. It is processed and extracted from the bulbs of wild or artificially cultivated lilies, and the underground bulbs contain more than 70% starch. It has extremely high nutritional value, rich in components such as vitamin B1, B2, C, etc., and also contains amino acids, calcium, phosphorus, iron, lily glycoside A, lily glycoside B, colchicine, etc. These components act on the human body comprehensively, not only having good nutritional and tonic effects, but also having auxiliary effects such as moistening the lungs and relieving cough, promoting wound healing, calming the mind and soothing the nerves, sedative and hypnotic, preventing gout, protecting the gastric mucosa, and enhancing immunity.

[0034] Chitosan oligosaccharide, also known as chitooligosaccharide and oligochitosan, is an oligosaccharide product with a degree of polymerization between 2 and 20 obtained by degrading chitosan through special bio-enzymatic technology (there are also reports of using chemical degradation and microwave degradation technologies). Its molecular weight ≤ 3200Da, and it is a low molecular weight product with good water solubility, great functional effects, and high biological activity. It has many unique functions such as higher solubility that chitosan does not have, being completely soluble in water, and being easily absorbed and utilized by organisms, and its effect is 14 times that of chitosan.

[0035] Papaya powder is made from papayas. The "papain" contained in papaya fruits has the effects of promoting digestion and anti-aging on the human body. Papaya powder contains rich papain, lemon enzyme, carotene, protein, vitamin C, B, and minerals such as calcium and phosphorus.

[0036] Gardenia extract is a reddish-brown powdery extract product of the fruits of the plant Gardenia jasminoides Ellis of the Rubiaceae family, and has the effects of purging fire and relieving restlessness, clearing away heat and promoting diuresis, cooling blood and detoxifying.

[0037] Example 1 The uric acid-lowering composition (S1) provided in this example includes the following raw materials by weight: 40 parts of collagen peptide, 10 parts of sophora flower extract, 8 parts of lily powder, 5 parts of chitosan oligosaccharide, 5 parts of papaya powder, 5 parts of gardenia extract, 1 part of compound vitamin, wherein the compound vitamin is vitamin B6: vitamin B12: vitamin C = 1:1:2.

[0038] Example 2 The uric acid-lowering composition (S2) provided in this example includes the following raw materials by weight: 80 parts of collagen peptide, 20 parts of sophora flower extract, 15 parts of lily powder, 15 parts of chitosan oligosaccharide, 15 parts of papaya powder, 15 parts of gardenia extract, 4 parts of compound vitamin. Among them, the compound vitamin is vitamin B6: vitamin D3: vitamin C = 1:1:2.

[0039] Example 3 The uric acid-lowering composition (S3) provided in this example includes the following raw materials by weight: 60 parts of collagen peptide, 16 parts of sophora japonica extract, 12 parts of lily powder, 10 parts of chitosan oligosaccharide, 10 parts of papaya powder, 10 parts of gardenia extract, 2 parts of compound vitamins, wherein the compound vitamins are vitamin B6: vitamin B12: vitamin D3: vitamin C = 1:1:1:3.

[0040] Animal experiment evaluation Randomly select 90 male KM mice at 8 weeks old and raise them for one week, then randomly divide them into groups (the treatment conditions of each group are shown in Table 1). The experimental period is 4 weeks. After 4 weeks, the serum uric acid level of the mice is detected, and the results are shown in Table 2.

[0041] Table 1 Grouping of experimental animals and drug treatment

[0042] Table 2 Serum uric acid level of mice after 4 weeks of drug administration

[0043] As can be seen from Table 2, after 4 weeks of drug administration, compared with the normal control group, the uric acid level in the model control group increased significantly, indicating that the model was successfully established. Compared with the model group, the positive control group, compositions S1, S2, and S3 could significantly reduce the serum uric acid level. From the results, it can be seen that the compositions provided by the present invention all have a significant uric acid-lowering effect.

[0044] As described above, it is only the specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art within the technical scope disclosed by the present invention can easily think of changes or substitutions, which should all be covered within the protection scope of the present invention. Therefore, the protection scope of the present invention should be subject to the protection scope of the claimed rights.

Claims

1. A uric acid-lowering composition, characterized in that, By weight parts, the raw materials of the composition include: 40 - 80 parts of collagen peptide, 10 - 20 parts of sophora japonica extract, 8 - 15 parts of lily powder, 5 - 15 parts of chitosan oligosaccharide, 5 - 15 parts of papaya powder, 5 - 15 parts of gardenia extract, and 1 - 4 parts of compound vitamin.

2. The anti-hyperuricemic composition according to claim 1, wherein The compound vitamin includes vitamin B6 and vitamin C.

3. The uric acid-lowering composition according to claim 1, wherein The compound vitamin further includes vitamin B12 and vitamin D.

4. The uric acid-lowering composition according to claim 1, wherein The collagen peptide is pure fish scale collagen peptide.

5. The uric acid-lowering composition according to claim 1, wherein The molecular weight of the chitosan oligosaccharide is not more than 2000 Da.

6. The preparation method of the uric acid-lowering composition according to claim 1, characterized in that, By weight parts, take 40 - 80 parts of collagen peptide, 10 - 20 parts of sophora japonica extract, 8 - 15 parts of lily powder, 5 - 15 parts of chitosan oligosaccharide, 5 - 15 parts of papaya powder, 5 - 15 parts of gardenia extract, and 1 - 4 parts of compound vitamin, and mix evenly to obtain.

7. Use of the uric acid - lowering composition according to claim 1 in the preparation of health - care functional foods and drugs.

8. A health product, characterized in that, The health - care product contains the uric acid - lowering composition according to any one of claims 1 - 2.

9. The health care product according to claim 1, characterized in that, The health - care product is an oral liquid, a liquid beverage, a solid beverage, jelly or candy.

Images